Access to Innovative Treatments Act of 2026
Official title: To amend title XVIII of the Social Security Act to provide a review process for adverse national coverage determinations with respect to drug coverage under the Medicare program.
What Do You Think?
How would you vote?
Vote to see the result.
What Happened in Congress?
Not yet voted on the floor.
Where the Bill Stands
- Introduced, done
- Committee, current stage
- Floor Vote, not yet
- Outcome, not yet
What This Bill Does
This bill requires the Centers for Medicare & Medicaid Services (CMS) to review adverse national coverage determinations of drugs under Medicare within 30 days of receiving a request to do so.
Specifically, the CMS must review within 30 days any denials or limitations of coverage that are inconsistent with the drug's approval by the Food and Drug Administration (FDA). The bill's requirements do not apply if the CMS already conducted such a review within a two-year period.
The bill also prohibits the CMS from applying prior coverage determinations that were made for drugs before they were approved by the FDA if such determinations are inconsistent with the drug's approval.
Sponsors
Related Documents
Timeline
- Library of CongressIntroduced in House
- House floor actionsReferred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Introduced
- Committee
Comments
Comments with insults, hate speech or personal information are removed.